GNOM vs. SBIO
Compare and contrast key facts about Global X Genomics & Biotechnology ETF (GNOM) and ALPS Medical Breakthroughs ETF (SBIO).
GNOM and SBIO are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. GNOM is a passively managed fund by Global X that tracks the performance of the Solactive Genomics Index. It was launched on Apr 5, 2019. SBIO is a passively managed fund by SS&C that tracks the performance of the S-Network Medical Breakthroughs Index. It was launched on Dec 31, 2014. Both GNOM and SBIO are passive ETFs, meaning that they are not actively managed but aim to replicate the performance of the underlying index as closely as possible.
Performance
GNOM vs. SBIO - Performance Comparison
Loading graphics...
GNOM vs. SBIO - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|---|
GNOM Global X Genomics & Biotechnology ETF | -2.79% | 18.65% | -15.99% | -8.63% | -36.27% | -15.93% | 51.52% | 1.56% |
SBIO ALPS Medical Breakthroughs ETF | 3.20% | 55.07% | 3.81% | 8.68% | -28.08% | -17.55% | 21.17% | 14.93% |
Returns By Period
In the year-to-date period, GNOM achieves a -2.79% return, which is significantly lower than SBIO's 3.20% return.
GNOM
- 1D
- 1.02%
- 1M
- -6.22%
- YTD
- -2.79%
- 6M
- 12.23%
- 1Y
- 44.15%
- 3Y*
- -3.13%
- 5Y*
- -13.13%
- 10Y*
- —
SBIO
- 1D
- 0.99%
- 1M
- 3.89%
- YTD
- 3.20%
- 6M
- 36.23%
- 1Y
- 95.78%
- 3Y*
- 26.37%
- 5Y*
- 1.76%
- 10Y*
- 9.75%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
GNOM vs. SBIO - Expense Ratio Comparison
Both GNOM and SBIO have an expense ratio of 0.50%.
Return for Risk
GNOM vs. SBIO — Risk / Return Rank
GNOM
SBIO
GNOM vs. SBIO - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Global X Genomics & Biotechnology ETF (GNOM) and ALPS Medical Breakthroughs ETF (SBIO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| GNOM | SBIO | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 1.43 | 2.92 | -1.50 |
Sortino ratioReturn per unit of downside risk | 2.04 | 3.57 | -1.53 |
Omega ratioGain probability vs. loss probability | 1.26 | 1.45 | -0.19 |
Calmar ratioReturn relative to maximum drawdown | 2.25 | 5.66 | -3.41 |
Martin ratioReturn relative to average drawdown | 7.43 | 19.94 | -12.51 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| GNOM | SBIO | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.43 | 2.92 | -1.50 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.39 | 0.05 | -0.44 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | — | 0.29 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.13 | 0.23 | -0.36 |
Correlation
The correlation between GNOM and SBIO is 0.84, which is considered to be high. That indicates a strong positive relationship between their price movements. Having highly-correlated positions in a portfolio may signal a lack of diversification, potentially leading to increased risk during market downturns.
Dividends
GNOM vs. SBIO - Dividend Comparison
GNOM's dividend yield for the trailing twelve months is around 1.41%, while SBIO has not paid dividends to shareholders.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
GNOM Global X Genomics & Biotechnology ETF | 1.41% | 1.37% | 0.00% | 0.00% | 0.00% | 0.03% | 0.14% | 0.00% | 0.00% | 0.00% |
SBIO ALPS Medical Breakthroughs ETF | 0.00% | 0.00% | 3.55% | 0.22% | 0.00% | 0.00% | 0.00% | 0.04% | 2.79% | 1.77% |
Drawdowns
GNOM vs. SBIO - Drawdown Comparison
The maximum GNOM drawdown since its inception was -75.00%, which is greater than SBIO's maximum drawdown of -63.06%. Use the drawdown chart below to compare losses from any high point for GNOM and SBIO.
Loading graphics...
Drawdown Indicators
| GNOM | SBIO | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -75.00% | -63.06% | -11.94% |
Max Drawdown (1Y)Largest decline over 1 year | -18.17% | -15.08% | -3.09% |
Max Drawdown (5Y)Largest decline over 5 years | -72.29% | -53.67% | -18.62% |
Max Drawdown (10Y)Largest decline over 10 years | — | -63.06% | — |
Current DrawdownCurrent decline from peak | -59.83% | -13.79% | -46.04% |
Average DrawdownAverage peak-to-trough decline | -40.12% | -28.70% | -11.42% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 5.51% | 4.28% | +1.23% |
Volatility
GNOM vs. SBIO - Volatility Comparison
The current volatility for Global X Genomics & Biotechnology ETF (GNOM) is 10.76%, while ALPS Medical Breakthroughs ETF (SBIO) has a volatility of 12.61%. This indicates that GNOM experiences smaller price fluctuations and is considered to be less risky than SBIO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| GNOM | SBIO | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 10.76% | 12.61% | -1.85% |
Volatility (6M)Calculated over the trailing 6-month period | 19.71% | 22.09% | -2.38% |
Volatility (1Y)Calculated over the trailing 1-year period | 31.21% | 33.43% | -2.22% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 33.65% | 33.55% | +0.10% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 34.30% | 33.34% | +0.96% |